<?xml version="1.0" encoding="UTF-8"?>
<p>We have provided an analysis of all antibiotics that were included in the EMA, Member States and EC harmonisation strategy between 2007 and 2020 to address inappropriate use of frequently used, mostly ‘old’, antibiotics. We found that 15 referral procedures were triggered; for all of them a positive benefit–risk balance was confirmed. The therapeutic use was restricted for all included antibiotics. Cephalosporins and penicillins were the two most represented classes of antibiotics in the study. According to the European Centre for Disease Prevention and Control annual report on antimicrobial consumption from 2017, those two classes (together with macrolides and tetracyclines) are among the most consumed of the EU antibacterial medicines for systemic use [
 <xref rid="r14" ref-type="bibr">14</xref>]. Since 2013, the European regulatory network has moved from Article 30 to Article 31 of Directive 2001/83/EC because of, among others, the complexity of engaging with multiple marketing authorisation holders. This has not let to major differences in the outcome of the Article 30 compared with the Article 31.
</p>
